Julie Gralow
Expertise in
7
conditions

Dr. Julie Gralow

Oncology
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
7
conditions
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 

Overview

Julie Gralow is an Oncologist in Seattle, Washington. Dr. Gralow is highly rated in 7 conditions, according to our data. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, HER-2 Positive Breast Cancer, and Paget Disease of the Breast.

Her clinical research consists of co-authoring 168 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in WA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

PacificSource
  • PPO

Locations

Rachel Loschiavo Pa-C
825 Eastlake Ave E, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Drug
Study Drug: Carvedilol
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drug: Olaparib
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women With Early Stage Breast Cancer
Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women With Early Stage Breast Cancer
Enrollment Status: Completed
Publish Date: December 07, 2022
Intervention Type: Procedure
Study Phase: Not Applicable
View 8 Less Clinical Trials

168 Total Publications

Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.
Journal: JAMA oncology
Published: December 11, 2025
Similar Doctors
Expertise in
23
conditions
Dr. Ajay Gopal
Oncology
Expertise in
23
conditions
Dr. Ajay Gopal
Oncology

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (0.8 miles away)
206-288-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ajay Gopal is an Oncologist in Seattle, Washington. Dr. Gopal is highly rated in 23 conditions, according to our data. His top areas of expertise are Follicular Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and B-Cell Lymphoma.

Expertise in
19
conditions
Dr. John Pagel
Oncology
Expertise in
19
conditions
Dr. John Pagel
Oncology

Swedish Cardiovascular RSRCH

1221 Madison St Ste 1020, 
Seattle, WA 
 (2.2 miles away)
206-215-2658
Languages Spoken:
English
See accepted insurances

John Pagel is an Oncologist in Seattle, Washington. Dr. Pagel is highly rated in 19 conditions, according to our data. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
9
conditions
Dr. Petros Grivas
Oncology
Expertise in
9
conditions
Dr. Petros Grivas
Oncology

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (0.8 miles away)
206-520-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Petros Grivas is an Oncologist in Seattle, Washington. Dr. Grivas is highly rated in 9 conditions, according to our data. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Endoscopy.

Frequently Asked Questions about Dr. Julie Gralow

How do I make an appointment with Dr. Julie Gralow?

You can book an appointment with Dr. Julie Gralow by calling their office at 208-288-7722. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Julie Gralow a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Julie Gralow is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Julie Gralow specialize in?

While Dr. Julie Gralow is a Oncology, they have specific expertise in Breast Cancer, Inflammatory Breast Cancer, and HER-2 Positive Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Julie Gralow participate in research or clinical trials?

Yes. Dr. Julie Gralow has published 168 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Julie Gralow's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Julie Gralow accept my insurance?

Dr. Julie Gralow accepts most major insurance plans, including PacificSource. We recommend calling the office directly at 208-288-7722 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gralow's expertise for a condition
ConditionClose
View All 8 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile